Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure - DAPA-HF

Exclusion Criteria

• • Receiving therapy with an SGLT2 inhibitor within 8 weeks prior to enrolment or previous intolerance of an SGLT2 inhibitor
• • Type 1 diabetes mellitus
• • Symptomatic hypotension or systolic BP <95 mmHg at 2 out of 3 measurements either at visit 1 or visit 2
• • Current acute decompensated HF or hospitalization due to decompensated HF <4 weeks prior to enrolment
• • MI, unstable angina, stroke or transient ischemic attack within 12 weeks prior to enrolment
• • Coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting) or valvular repair/replacement within 12 weeks prior to enrolment or planned to undergo any of these operations after randomization
• • Implantation of a CRT within 12 weeks prior to enrolment or intent to implant a CRT device
• • Previous cardiac transplantation or implantation of a ventricular assistance device or similar device, or implantation expected after randomization
• • HF due to restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, hypertrophic (obstructive) cardiomyopathy or uncorrected primary valvular disease
• • Symptomatic bradycardia or second or third degree heart block without a pacemaker
• • Severe (eGFR <30 mL/min/1.73 m^2 by CKD-EPI), unstable or rapidly progressing renal disease at the time of randomization